company background image
DVL

dorsaViASX:DVL Stock Report

Market Cap

AU$6.7m

7D

5.6%

1Y

-57.8%

Updated

20 Oct, 2021

Data

Company Financials
DVL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

DVL Overview

dorsaVi Ltd engages in the development and sale of motion analysis technologies in Australia, Europe, and the United States.

Price History & Performance

Summary of all time highs, changes and price drops for dorsaVi
Historical stock prices
Current Share PriceAU$0.019
52 Week HighAU$0.018
52 Week LowAU$0.08
Beta1.39
1 Month Change-13.64%
3 Month Change-29.63%
1 Year Change-57.78%
3 Year Change-72.86%
5 Year Change-95.58%
Change since IPO-95.25%

Recent News & Updates

Jan 03
A Look At dorsaVi's (ASX:DVL) CEO Remuneration

A Look At dorsaVi's (ASX:DVL) CEO Remuneration

This article will reflect on the compensation paid to Andrew Ronchi who has served as CEO of dorsaVi Ltd ( ASX:DVL...

Shareholder Returns

DVLAU BiotechsAU Market
7D5.6%1.1%1.7%
1Y-57.8%1.7%20.2%

Return vs Industry: DVL underperformed the Australian Biotechs industry which returned 1.7% over the past year.

Return vs Market: DVL underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is DVL's price volatile compared to industry and market?
DVL volatility
DVL Beta1.39
Industry Beta1.62
Market Beta1

Stable Share Price: DVL is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: DVL's weekly volatility has decreased from 20% to 7% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008n/aAndrew Ronchihttps://www.dorsavi.com

dorsaVi Ltd engages in the development and sale of motion analysis technologies in Australia, Europe, and the United States. The company provides ViMove, a wearable sensor technology, which provides patient care and exercise plans, patient engagement and recovery programs, and rehabilitation programs; ViSafe, a wearable sensor technology that tracks, analyzes, and reports how workforce moves and reviews and pinpoints unsafe work practices that leads to workplace injury; and myViSafe technology for organizations and on-site clinicians to identify and mitigate injury risk in the workplace and drive behavioral changes. It also offers ViPerform, a wearable and wireless movement sensor technology that offers objective data to assess risk of sport injury, and guides athletic training and recovery programs; telehealth solutions; and professional suites.

dorsaVi Fundamentals Summary

How do dorsaVi's earnings and revenue compare to its market cap?
DVL fundamental statistics
Market CapAU$6.68m
Earnings (TTM)-AU$2.03m
Revenue (TTM)AU$1.87m

3.6x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DVL income statement (TTM)
RevenueAU$1.87m
Cost of RevenueAU$166.33k
Gross ProfitAU$1.70m
ExpensesAU$3.73m
Earnings-AU$2.03m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0058
Gross Margin91.10%
Net Profit Margin-108.52%
Debt/Equity Ratio73.8%

How did DVL perform over the long term?

See historical performance and comparison

Valuation

Is dorsaVi undervalued compared to its fair value and its price relative to the market?

3.09x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DVL's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DVL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DVL is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: DVL is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DVL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DVL is good value based on its PB Ratio (3.1x) compared to the AU Biotechs industry average (4.8x).


Future Growth

How is dorsaVi forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as dorsaVi has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has dorsaVi performed over the past 5 years?

-0.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DVL is currently unprofitable.

Growing Profit Margin: DVL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DVL is unprofitable, and losses have increased over the past 5 years at a rate of 0.6% per year.

Accelerating Growth: Unable to compare DVL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DVL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: DVL has a negative Return on Equity (-93.76%), as it is currently unprofitable.


Financial Health

How is dorsaVi's financial position?


Financial Position Analysis

Short Term Liabilities: DVL's short term assets (A$4.8M) exceed its short term liabilities (A$1.5M).

Long Term Liabilities: DVL's short term assets (A$4.8M) exceed its long term liabilities (A$1.4M).


Debt to Equity History and Analysis

Debt Level: DVL's debt to equity ratio (73.8%) is considered high.

Reducing Debt: DVL's debt to equity ratio has increased from 0.01% to 73.8% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DVL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: DVL has less than a year of cash runway if free cash flow continues to grow at historical rates of 20.3% each year.


Dividend

What is dorsaVi current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DVL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DVL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DVL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DVL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DVL's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

13.3yrs

Average board tenure


CEO

Andrew Ronchi

13.67yrs

Tenure

AU$291,451

Compensation

Dr. Andrew James Ronchi, B.App.Sci. (Physio), PhD (RMIT Eng), GAICD, co-founded dorsaVi Ltd. and serves as its Managing Director. He has been Chief Executive Officer of dorsaVi Ltd since February 2008 and...


CEO Compensation Analysis

Compensation vs Market: Andrew's total compensation ($USD217.91K) is about average for companies of similar size in the Australian market ($USD302.06K).

Compensation vs Earnings: Andrew's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: DVL's board of directors are seasoned and experienced ( 13.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DVL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.9%.


Top Shareholders

Company Information

dorsaVi Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: dorsaVi Ltd
  • Ticker: DVL
  • Exchange: ASX
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$6.677m
  • Shares outstanding: 351.43m
  • Website: https://www.dorsavi.com

Number of Employees


Location

  • dorsaVi Ltd
  • 86 Denmark Street
  • Kew
  • Victoria
  • 3101
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/20 15:29
End of Day Share Price2021/10/20 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.